The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1212
ISSUE1212
July 4, 2005
Pegaptanib Sodium (Macugen) for Macular Degeneration
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Pegaptanib Sodium (Macugen) for Macular Degeneration
July 4, 2005 (Issue: 1212)
The FDA has approved pegaptanib sodium (Macugen - Pfizer/Eyetech) as an intravitreous injection for treatment of all subtypes of neovascular (wet) age-related macular degeneration (AMD). The only other approved treatment for this condition is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.